Interferon-associated therapies toward HIV control: The back and forth - Institut Pasteur Access content directly
Journal Articles Cytokine and Growth Factor Reviews Year : 2018

Interferon-associated therapies toward HIV control: The back and forth

Abstract

Human immunodeficiency virus (HIV) induces a persistent and incurable infection. However, the combined antiretroviral treatment (cART) has markedly changed the evolution of the infection and transformed a deadly disease into a manageable chronic infection. Withdrawal of cART generally leads though to resumption of the viral replication. The eradication of the virus from its cellular and anatomical reservoirs remains a goal-to-achieve for a cure. In this context, developing novel therapies contributing to this aim are an important field of research. Type I IFN has antiviral activity, which, before the presence of efficient anti-HIV drugs, has led to the testing of IFN-based therapeutic strategies during the early years of the pandemic. A historical overview of the results and its limitations that were put into light are reviewed here. In addition, several lessons could be drawn. For instance, the efficacy of the IFN-I depends on the timing of its administration and the context. Thus, the persistence of an endogenous IFN-signature, such as that generally observed in viremic patients, seems to be associated with a lower efficacy of IFN. Based on the lessons from previous trials, and in the context of cART and research for a cure, type I Interferon has regained interest and novel therapeutic approaches are currently tested in combination with cART, some with disappointing, other with encouraging results with regard to a reduction in the size of the HIV reservoir and/or delays in viral rebound after cessation of cART. Additional strategies are currently developed in addition to improve the antiviral function of the IFN-I, by using for instance other IFN subtypes than IFN-Iα2. In parallel, the development of innovative strategies aimed at counteracting the excessive activation of the IFN-pathways have been continued and their results are reviewed here as well. Altogether, the use of IFN-I in anti-HIV therapies has gone through distinct phases and many lessons could be drawn. Novel combinations are currently be tested that might provide interesting results.
Fichier principal
Vignette du fichier
IFN back forth_NN-MMT-final.pdf (1.08 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

pasteur-01969821 , version 1 (04-01-2019)

Licence

Attribution - NonCommercial - ShareAlike

Identifiers

Cite

Nicolas Noel, Béatrice Jacquelin, Nicolas Huot, Cécile Goujard, Olivier Lambotte, et al.. Interferon-associated therapies toward HIV control: The back and forth. Cytokine and Growth Factor Reviews, 2018, 40, pp.99-112. ⟨10.1016/j.cytogfr.2018.03.004⟩. ⟨pasteur-01969821⟩
216 View
1135 Download

Altmetric

Share

Gmail Facebook X LinkedIn More